NEUBASE THERAPEUTICS INC
COM · CUSIP 64132K102
1
institutional holders
-2 vs Q2 2023
47.0k
shares reported held*
$40.9kreported value*
0 new
0 added
0 reduced
2 sold out
net sold ≈ $43.7k (-50.2k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.87.
Trends to Q3 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 45 |
| Q4 2022 | 36 |
| Q1 2023 | 37 |
| Q2 2023 | 3 |
| Q3 2023 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 9 | 22 |
| Q1 2023 | 9 | 10 |
| Q2 2023 | 1 | 37 |
| Q3 2023 | 0 | 2 |
Biggest buyers
| None |
Biggest sellers
| Decheng Capital Management III (Cayman), LLC | Sold out | -50.0k |
| IFP Advisors, Inc | Sold out | -200 |
Holders, Q3 2023
| Manager | Shares | Change |
|---|---|---|
| Carnegie Mellon University 0.05% of their portfolio | 47.0k $40.9k | Unchanged |